{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:15:00Z","timestamp":1770884100708,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"13-14","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.drudis.2013.04.001","type":"journal-article","created":{"date-parts":[[2013,4,8]],"date-time":"2013-04-08T09:07:17Z","timestamp":1365412037000},"page":"637-643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis"],"prefix":"10.1016","volume":"18","author":[{"given":"Martyn K.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Caminis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Brunkow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2013.04.001_bib0005","doi-asserted-by":"crossref","first-page":"J156","DOI":"10.1016\/j.jaut.2011.11.003","article-title":"Twin studies in autoimmune disease: genetics, gender and environment","volume":"38","author":"Bogdanos","year":"2012","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.drudis.2013.04.001_bib0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrg2554","article-title":"Human genetic variation and its contribution to complex traits","volume":"10","author":"Frazer","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.drudis.2013.04.001_bib0015","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1182\/blood-2008-06-077891","article-title":"The GPIIb\/IIIa (integrin \u03b1IIb\u03b23) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend","volume":"112","author":"Coller","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2013.04.001_bib0020","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1055\/s-0032-1328881","article-title":"Drugs that affect platelet function","volume":"38","author":"Scharf","year":"2012","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.drudis.2013.04.001_bib0025","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1136\/jmg.25.3.200","article-title":"Sclerosteosis","volume":"25","author":"Beighton","year":"1988","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.drudis.2013.04.001_bib0030","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1034\/j.1399-0004.2003.00036.x","article-title":"The natural history of sclerosteosis","volume":"63","author":"Hamersma","year":"2003","journal-title":"Clin. Genet."},{"key":"10.1016\/j.drudis.2013.04.001_bib0035","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1259\/0007-1285-49-587-934","article-title":"The radiology of sclerosteosis","volume":"49","author":"Beighton","year":"1976","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.drudis.2013.04.001_bib0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1750-1172-4-5","article-title":"Osteopetrosis","volume":"4","author":"Stark","year":"2009","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.drudis.2013.04.001_bib0045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1212\/WNL.33.3.267","article-title":"Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship","volume":"33","author":"Stein","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2013.04.001_bib0050","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1210\/jc.2005-1235","article-title":"Bone mineral density in sclerosteosis; affected individuals and gene carriers","volume":"90","author":"Gardner","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.drudis.2013.04.001_bib0055","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.rcl.2010.02.014","article-title":"Physiology of bone loss","volume":"48","author":"Clarke","year":"2010","journal-title":"Radiol. Clin. North Am."},{"key":"10.1016\/j.drudis.2013.04.001_bib0060","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.drudis.2013.04.001_bib0065","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s00198-010-1419-7","article-title":"Medical costs of osteoporosis in the elderly Medicare population","volume":"22","author":"Blume","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.drudis.2013.04.001_bib0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrd3299","article-title":"Emerging therapeutic opportunities for skeletal restoration","volume":"10","author":"Kawai","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2013.04.001_bib0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1086\/301721","article-title":"Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21","volume":"62","author":"Van Hul","year":"1998","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.drudis.2013.04.001_bib0080","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/302416","article-title":"Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21","volume":"64","author":"Balemans","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.drudis.2013.04.001_bib0085","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.drudis.2013.04.001_bib0090","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.drudis.2013.04.001_bib0095","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.10401","article-title":"A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population","volume":"110","author":"Staehling-Hampton","year":"2002","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.drudis.2013.04.001_bib0100","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","author":"Balemans","year":"2002","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.drudis.2013.04.001_bib0105","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1101\/gr.3437105","article-title":"Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease","volume":"15","author":"Loots","year":"2005","journal-title":"Genome Res."},{"key":"10.1016\/j.drudis.2013.04.001_bib0110","first-page":"1794","article-title":"Van Buchem disease: clinical, biochemical and densitometric features of patients and disease carriers","author":"Van Lierop","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.drudis.2013.04.001_bib0115","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev.bioeng.8.061505.095721","article-title":"Biomechanical and molecular regulation of bone remodeling","volume":"8","author":"Robling","year":"2006","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.drudis.2013.04.001_bib0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.gene.2012.04.076","article-title":"Mechanical regulation of signaling pathways in bone","volume":"503","author":"Thompson","year":"2012","journal-title":"Gene"},{"key":"10.1016\/j.drudis.2013.04.001_bib0125","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2013.04.001_bib0130","doi-asserted-by":"crossref","first-page":"24113","DOI":"10.1074\/jbc.M301716200","article-title":"Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity","volume":"278","author":"Kusu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2013.04.001_bib0135","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.drudis.2013.04.001_bib0140","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","article-title":"High bone density due to a mutation in LDL-receptor-related protein 5","volume":"346","author":"Boyden","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2013.04.001_bib0145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/338450","article-title":"A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait","volume":"70","author":"Little","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.drudis.2013.04.001_bib0150","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"van Bezooijen","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drudis.2013.04.001_bib0155","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2013.04.001_bib0160","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1359\/jbmr.061002","article-title":"Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation","volume":"22","author":"van Bezooijen","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.drudis.2013.04.001_bib0165","doi-asserted-by":"crossref","first-page":"41614","DOI":"10.1074\/jbc.M110.153890","article-title":"Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways","volume":"285","author":"Krause","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2013.04.001_bib0170","doi-asserted-by":"crossref","first-page":"10890","DOI":"10.1074\/jbc.M807994200","article-title":"Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation","volume":"284","author":"Veverka","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2013.04.001_bib0175","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bbrc.2009.01.062","article-title":"NMR structure of the Wnt modulator protein Sclerostin","volume":"380","author":"Weidauer","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drudis.2013.04.001_bib0180","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.str.2011.07.005","article-title":"Wnt antagonists bind through a short peptide to the first \u03b2-propeller domain of LRP5\/6","volume":"19","author":"Bourhis","year":"2011","journal-title":"Structure"},{"key":"10.1016\/j.drudis.2013.04.001_bib0185","doi-asserted-by":"crossref","first-page":"26464","DOI":"10.1074\/jbc.M112.350108","article-title":"Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors","volume":"287","author":"Holdsworth","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2013.04.001_bib0190","doi-asserted-by":"crossref","first-page":"19489","DOI":"10.1074\/jbc.M110.190330","article-title":"Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function","volume":"286","author":"Leupin","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2013.04.001_bib0195","doi-asserted-by":"crossref","first-page":"e7930","DOI":"10.1371\/journal.pone.0007930","article-title":"Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo","volume":"4","author":"Choi","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2013.04.001_bib0200","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/jbmr.345","article-title":"Sclerostin is a locally acting regulator of late-osteoblast\/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism","volume":"26","author":"Atkins","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"23","key":"10.1016\/j.drudis.2013.04.001_bib0205","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"2008","author":"Li","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.drudis.2013.04.001_bib0210","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/jbmr.161","article-title":"Sclerostin: a gem from the genome leads to bone-building antibodies","volume":"25","author":"Paszty","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.drudis.2013.04.001_bib0215","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/er.2011-1060","article-title":"Sclerostin and dickkopf-1 as therapeutic targets in bone diseases","volume":"33","author":"Ke","year":"2012","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.drudis.2013.04.001_bib0220","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.drudis.2013.04.001_bib0225","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.drudis.2013.04.001_bib0230","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1210\/en.2011-0252","article-title":"Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats","volume":"152","author":"Li","year":"2011","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.drudis.2013.04.001_bib0235","doi-asserted-by":"crossref","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","article-title":"Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway","volume":"6","author":"Wijenayaka","year":"2011","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"10.1016\/j.drudis.2013.04.001_bib0240","article-title":"Blosozumab, a humanised monoclonal antibody against sclerostin, demonstrated anabolic effects on bone in postmenopausal women","volume":"27","author":"McColm","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl 1","key":"10.1016\/j.drudis.2013.04.001_bib0245","article-title":"Inhibition with AMG 785 in postmenopausal women with low bone density: phase 2 trial results","volume":"27","author":"McClung","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.drudis.2013.04.001_bib0250","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2012-100819","article-title":"Clinical application of exome sequencing in undiagnosed genetic conditions","volume":"49","author":"Need","year":"2012","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.drudis.2013.04.001_bib0255","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature09534","article-title":"A map of human genome variation from population scale sequencing","volume":"467","author":"The 1000 Genomes Project Consortium","year":"2010","journal-title":"Nature"},{"issue":"7121","key":"10.1016\/j.drudis.2013.04.001_bib0260","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/nature05413","article-title":"An SCN9A channelopathy causes congenital inability to experience pain","volume":"444","author":"Cox","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2013.04.001_bib0265","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.drudis.2013.04.001_bib0270","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/342448a0","article-title":"Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins","volume":"342","author":"Brown","year":"1989","journal-title":"Nature"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644613000950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644613000950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:14:47Z","timestamp":1761221687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644613000950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":54,"journal-issue":{"issue":"13-14","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1359644613000950"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2013.04.001","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2013.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}